13 October 2025
13 October 2025
The latest amendment, which has been endorsed by Congress, could be the Act’s catalyst after a year in legislative limbo.
Marketing and manufacturing practices for compounded GLP-1RA drugs have come under FDA scrutiny, prompting policy changes.
BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.
The pharma will now offer select branded medications for up to 80% less to cash-paying Americans through the TrumpRx.gov DTC platform.
The approval is supported by a combination of current clinical data and model-informed drug development techniques.
The acquisition would grant J&J access to rusfertide, which has demonstrated promise in late-stage trials for polycythaemia vera.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
